First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL

GDC-0853 is a selective, reversible, and non-covalent inhibitor of Bruton’s tyrosine kinase (BTK) that does not require interaction with the Cys481 residue for activity. In this first-in-human phase 1 study we evaluated safety, tolerability, pharmacokinetics, and activity of GDC-0853 in patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Byrd, John C., Smith, Stephen, Wagner-Johnston, Nina, Sharman, Jeff, Chen, Andy I., Advani, Ranjana, Augustson, Bradley, Marlton, Paula, Renee Commerford, S., Okrah, Kwame, Liu, Lichuan, Murray, Elaine, Penuel, Elicia, Ward, Ashley F., Flinn, Ian W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849192/
https://www.ncbi.nlm.nih.gov/pubmed/29560128
http://dx.doi.org/10.18632/oncotarget.24310

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849192/
https://www.ncbi.nlm.nih.gov/pubmed/29560128
http://dx.doi.org/10.18632/oncotarget.24310

Ejemplares similares